Quaternium-73 Regulatory Status: What Cosmetic Manufacturers Need to Know

For cosmetic manufacturers and ingredient buyers, the Quaternium-73 regulatory status cannot be reduced to a global “approved” or “not approved” answer. Cosmetic ingredient rules differ between the European Union, United States, China, Japan and other markets, while the intended function, concentration, product category and marketing claims can also affect the compliance assessment.

 

This distinction is particularly important for Quaternium-73 because commercial literature may describe it in connection with antimicrobial activity, blemish-prone skin formulations or preservative-supporting applications. Those technical descriptions do not automatically establish a regulatory function in every jurisdiction.

 

A practical regulatory review therefore needs to answer several separate questions: Is the ingredient correctly identified? Is it prohibited or restricted in the target market? Is its intended function subject to a positive list? Does the proposed concentration comply with applicable requirements? Are the finished-product claims appropriate? Finally, is there sufficient safety and supplier documentation to support the finished-product assessment?

 

For international buyers, this leads to a useful principle:

 

INCI recognition, database listing, regulatory authorization, permitted function and finished-product compliance are separate questions and should be evaluated separately.

 

This guide examines Quaternium-73 cosmetic regulations from that procurement-oriented perspective.

 

Quaternium-73 INCI Name, CAS Number and Regulatory Identity

 

Before assessing Quaternium-73 regulatory requirements, buyers should establish that the material being offered corresponds to the substance being reviewed in regulatory databases and technical documentation.

 

Basic identifiers commonly associated with the ingredient include:

 

Regulatory Identifier	Information
INCI name	Quaternium-73
CAS No.	15763-48-1
EC No.	239-852-5
Common synonym encountered commercially	Pionin
Chemical class	Quaternary thiazolium compound

 

These identifiers should be consistent across the supplier's specification, COA, SDS and TDS. A trade name alone is insufficient for regulatory qualification because several suppliers can market chemically similar or identical ingredients under different commercial names.

 

For procurement teams, CAS identity is especially useful when comparing documentation, but a CAS number should not itself be interpreted as regulatory authorization. Similarly, a recognized Quaternium-73 INCI name establishes nomenclature rather than unrestricted permission to use the ingredient for every purpose.

 

That difference becomes important when the finished product is intended for multiple markets.

 

Quaternium-73 INCI Recognition vs Regulatory Approval

​​​​​​​

One of the most common mistakes in cosmetic ingredient sourcing is treating an INCI listing as an approval certificate.

 

For the EU, the European Commission explicitly states that its CosIng glossary does not constitute a list of ingredients authorized for use in cosmetic products. The Commission also notes that CosIng is an information database without legal value; Regulation (EC) No 1223/2009 and its Annexes determine whether and under what conditions substances may be used.

 

For a buyer investigating whether Quaternium-73 is allowed in cosmetics, the terminology should therefore be interpreted carefully:

 

Term	What It Tells the Buyer
INCI name	Standardized cosmetic ingredient nomenclature
Database entry	Information about an ingredient
Supplier recommended concentration	Technical formulation guidance
Regulatory restriction	Legally applicable condition in a specific market
Authorized preservative	Ingredient meets the relevant positive-list requirements for that function
Finished-product compliance	Complete product has met applicable market requirements

 

A supplier may therefore correctly provide an INCI name and still not be in a position to declare that every formulation containing the material is “EU approved,” “FDA approved” or globally compliant.

 

For regulatory and procurement teams, this distinction is much more useful than a generic certificate claiming worldwide compliance.

 

Quaternium-73 EU Regulatory Status: What Does CosIng Actually Mean?

 

The Quaternium-73 EU regulation question should start with Regulation (EC) No 1223/2009 rather than with a supplier brochure.

 

CosIng is valuable for checking cosmetic ingredient nomenclature and related information, but the European Commission specifically warns that the presence of an INCI name in the database does not mean the ingredient is approved for cosmetic use.

 

For a meaningful review of Quaternium-73 regulatory status in Europe, regulatory teams should consider the ingredient against the relevant parts of Regulation (EC) No 1223/2009, including its Annexes. Depending on the intended function, these include Annex II for prohibited substances, Annex III for restricted substances, Annex IV for permitted colorants, Annex V for permitted preservatives and Annex VI for permitted UV filters.

 

The regulatory review does not end with the ingredient.

 

Article 10 requires the responsible person to ensure that the cosmetic product undergoes a safety assessment before being placed on the EU market. Annex I requires the Cosmetic Product Safety Report to address the qualitative and quantitative composition, chemical identity, physical and chemical characteristics, stability, microbiological quality, impurities and relevant toxicological information.

 

Consequently, asking “Is Quaternium-73 allowed in EU cosmetics?” is only the beginning. The more commercially useful question is whether the proposed Quaternium-73 use, concentration and function can be supported within a compliant finished-product safety assessment.

 

Is Quaternium-73 an Approved Preservative in the EU?

 

This question deserves particular attention because antimicrobial terminology is easily misinterpreted.

 

Some commercial technical literature associates Quaternium-73 with antimicrobial activity or preservative-supporting applications. That does not mean Quaternium-73 is an approved preservative in the EU.

 

Under Regulation (EC) No 1223/2009, Annex V is specifically the List of Preservatives Allowed in Cosmetic Products.

 

A manufacturer should therefore not convert statements such as “antimicrobial ingredient” or “preservative synergist” into the legal claim “EU-approved preservative” without establishing that the substance and intended preservative use meet the current Annex V requirements.

 

The distinction is straightforward but important:

 

Antimicrobial activity is a technical property; preservative authorization is a regulatory status.

​​​​​​​

This matters to buyers because supplier marketing terminology can eventually appear in internal specifications, product dossiers and customer communications. Regulatory teams should verify the legal function independently rather than inheriting a description from a sales document.

 

Does Quaternium-73 Have a Maximum Use Level in EU Cosmetics?

 

Another common source of confusion is the difference between a supplier's formulation recommendation and a statutory concentration limit.

 

Commercial Quaternium-73 technical documentation can recommend concentrations around 0.001–0.005% for particular grades and applications. This information can be useful when establishing laboratory trials, but a supplier's recommended range is not automatically a Quaternium-73 EU concentration limit.

 

A regulatory maximum must come from the legislation applicable to the intended use.

 

This distinction should also be reflected in internal documentation. A product developer might select 0.003% because it falls within a supplier's recommended working range, while the safety assessor separately determines whether the concentration and exposure are acceptable for the intended finished product.

 

The same principle applies internationally. A regulatory limit established in one jurisdiction should not automatically be applied to another.

 

Taiwan illustrates this point clearly: its official list of preservatives allowed in cosmetic products identifies Quaternium-73 among photosensitizing dyes at a maximum concentration of 0.005%. That is jurisdiction-specific evidence, not a universal global limit.

 

Therefore, any statement about a Quaternium-73 maximum use level should specify whether it refers to technical supplier guidance or a legally applicable market requirement.

 

Quaternium-73 Regulatory Status in the United States: FDA and MoCRA

 

The American system is fundamentally different from the EU model, so statements such as “Quaternium-73 is FDA approved” should be avoided unless they refer to a regulatory mechanism that actually involves FDA approval.

 

FDA states that cosmetic products and ingredients generally do not require premarket approval, with the important exception of certain color additives. Companies marketing cosmetics remain legally responsible for ensuring that their products are safe, properly labeled and compliant with restrictions.

 

For this reason, the correct way to approach Quaternium-73 FDA cosmetic regulation is not to search for an “FDA approval certificate.”

 

Instead, a U.S. manufacturer should establish that the ingredient and finished product can be safely used under labeled or customary conditions, that the product is properly labeled and that its use does not cause the cosmetic to become adulterated or misbranded.

 

MoCRA has substantially expanded the compliance framework. Among other requirements, it introduced facility registration, cosmetic product listing, adverse-event obligations and safety substantiation requirements. The responsible person must ensure and maintain records supporting adequate substantiation of the safety of the cosmetic product.

 

For an importer sourcing cosmetic grade Quaternium-73 for a U.S. formulation, this makes traceable supplier documentation more important. However, neither facility registration nor product listing should be presented to customers as evidence that FDA has approved Quaternium-73.

 

Quaternium-73 Claims in the U.S.: When a Cosmetic Claim Creates a Different Regulatory Problem

 

Ingredient compliance and marketing claims are closely connected in the United States.

 

Under the FD&C Act, cosmetics include products intended for purposes such as cleansing, beautifying, promoting attractiveness or altering appearance. Products intended for diagnosis, cure, mitigation, treatment or prevention of disease—or to affect the structure or function of the body—can fall within the drug definition.

 

FDA also states that cosmetic labeling claims must be truthful and not misleading, and disease-treatment or structure/function claims can cause a product marketed as a cosmetic to be regulated as a drug.

 

This is particularly relevant to Quaternium-73 antimicrobial claims in cosmetics.

 

A cosmetic formulated for “blemish-prone skin” does not necessarily have the same regulatory positioning as a product claiming to “treat acne.” Likewise, a scalp-care shampoo and a product making disease-treatment claims should not be evaluated as if their regulatory implications were identical.

 

For U.S. brands, regulatory review should therefore cover not only the raw material but also website copy, packaging, product names, advertising and supporting evidence.

 

Quaternium-73 Regulatory Status in China: What Manufacturers Should Verify

 

For Quaternium-73 China cosmetic regulation, buyers should avoid relying on an English-language supplier statement that simply says “China compliant.”

 

China operates its own cosmetic ingredient and finished-product regulatory framework. Before a commercial purchase, the regulatory team should verify the current NMPA framework and applicable ingredient inventory for the precise Chinese ingredient identity, proposed use and product category.

 

The review should establish whether the ingredient is covered by the current framework for the proposed use, whether restrictions or specific conditions apply, and whether the proposed concentration and function are consistent with the finished-product route.

 

This becomes particularly important when a supplier uses several names for the same material. The English INCI name, Chinese ingredient name, CAS number and documentation supplied for the batch should be reconciled before regulatory approval.

 

If the ingredient or proposed use falls outside an established pathway, China's new cosmetic ingredient requirements may become relevant.

 

For procurement purposes, the safest practice is therefore not to ask only whether Quaternium-73 appears in a database. Ask the regulatory team to document the exact NMPA/ingredient-inventory basis supporting the intended product before commercial launch.

 

Quaternium-73 Regulatory Status in Japan: Ingredient Use and Product Classification

 

Japan also requires a market-specific assessment.

 

The Ministry of Health, Labour and Welfare publishes the Standards for Cosmetics and related regulatory materials. The Standards establish general safety requirements and restrictions concerning ingredients, including specific frameworks for preservatives, UV absorbers and tar colors.

 

Consequently, a Quaternium-73 Japan cosmetic regulation review should examine both the ingredient and its intended function rather than assuming that an INCI name accepted elsewhere automatically establishes Japanese compliance.

 

Product positioning is also important. Japan distinguishes ordinary cosmetics from quasi-drugs, and a product's claims and intended function can affect its regulatory pathway. This is particularly relevant for products positioned around acne, scalp concerns or anti-dandruff concepts.

 

A manufacturer planning a Japanese launch should therefore confirm the current Standards for Cosmetics, applicable ingredient restrictions, accepted labeling terminology and finished-product classification with its Japanese regulatory responsible party before finalizing the formula.

 

Quaternium-73 Global Regulatory Status: Why One Compliance Statement Is Not Enough

 

For international sourcing, the regulatory systems can be summarized more usefully by the questions they require manufacturers to answer:

 

Market	Primary Regulatory Question	Buyer Should Verify
European Union	Does the use comply with Regulation (EC) 1223/2009?	Annexes, intended function, CPSR and PIF
United States	Is the product safe, properly labeled and compliant with U.S. cosmetic law?	Safety substantiation, MoCRA obligations and claims
China	Is the ingredient/use covered by the current Chinese framework?	NMPA requirements and current ingredient inventory
Japan	Does the ingredient/use comply with Japanese cosmetic standards and product classification?	Standards for Cosmetics, restrictions and claims
Taiwan	Are applicable positive-list conditions met?	Listed function and concentration limits

 

This explains why a single document headed “Global Regulatory Certificate” rarely answers every question surrounding Quaternium-73 regulation by country.

 

International brands should establish a market matrix during formula development rather than completing one regulatory review and assuming it applies worldwide.

 

Does Quaternium-73 Need a Cosmetic Safety Assessment?

 

Regulatory acceptability does not remove the manufacturer's responsibility to establish finished-product safety.

 

In the EU, Article 10 requires a safety assessment before a cosmetic is placed on the market, while the Product Information File must contain the Cosmetic Product Safety Report and other specified information. The PIF must be maintained for ten years after the last batch is placed on the market.

 

The CPSR considers much more than an ingredient name. Annex I addresses quantitative composition, chemical identity, physicochemical characteristics, stability, microbiological quality, impurities, toxicological profile and exposure.

 

In the United States, MoCRA requires the responsible person to ensure and maintain adequate safety substantiation records. FDA explains that this can be supported by tests, studies, research, analyses or other scientifically robust information sufficient to support reasonable certainty that the product is safe.

 

For a Quaternium-73 safety assessment, buyers should therefore seek enough raw-material information to allow their safety assessor to evaluate identity, purity, impurities, concentration and exposure within the actual finished formula.

 

What Regulatory Documents Should Buyers Request From a Quaternium-73 Supplier?

 

The commercial value of a Quaternium-73 supplier is partly determined by the quality of the documentation accompanying the raw material.

 

Before approving cosmetic grade Quaternium-73, procurement and regulatory teams should obtain a current specification, batch-specific Quaternium-73 COA, Quaternium-73 TDS and Quaternium-73 SDS.

 

The specification and COA should allow the buyer to verify the identity and quality of the batch, including assay and other relevant quality parameters. The TDS should provide formulation information such as recommended use range, solubility, processing guidance, storage conditions and shelf life where available. The SDS serves a different purpose and should not be treated as a substitute for a cosmetic safety dossier.

 

Where available and relevant to the market, buyers may also request manufacturing-origin information, impurity information, test methodology, stability information and regulatory declarations.

 

The key point is that a statement such as “EU compliant” cannot replace the underlying Quaternium-73 regulatory documents needed by a responsible person, safety assessor, importer or finished-product manufacturer.

 

For international projects, document revision dates matter as well. A ten-year-old generic declaration should not automatically be treated as equivalent to a current regulatory review.

 

How to Evaluate a Reliable Quaternium-73 Supplier for Regulatory Compliance

 

Supplier qualification should connect quality assurance, regulatory review and formulation testing rather than treating them as separate purchasing tasks.

 

A buyer evaluating a reliable Quaternium-73 supplier should first confirm chemical identity and compare the specification against representative batch COAs. The regulatory team can then determine whether the documentation is adequate for the intended markets and whether additional safety or impurity information is required.

 

Only after that initial review does a representative sample become meaningful. R&D can evaluate the supplied material at the intended concentration and confirm solubility, compatibility, appearance and stability in the actual formulation.

 

CHEN LANG BIO TECH supports cosmetic manufacturers and raw-material buyers with batch-specific quality documents and technical information for Quaternium-73 qualification. For projects intended for multiple markets, we encourage customers to evaluate our documentation together with their own responsible person, safety assessor or local regulatory consultant rather than relying on a generic “global approval” statement.

 

That approach gives purchasing teams a more defensible basis for supplier approval.

 

Quaternium-73 Sample, MOQ, Price and Documentation for Bulk Buyers

 

For commercial sourcing, regulatory qualification should normally precede price negotiation.

 

A practical purchasing process begins with specification and document review, followed by regulatory screening and laboratory evaluation of a Quaternium-73 sample. Once R&D approves the material, procurement can compare packaging, Quaternium-73 MOQ, lead time and commercial terms.

 

This sequence is particularly relevant because Quaternium-73 is commonly evaluated at very low formulation concentrations. If a manufacturer uses 0.003%, a 1,000 kg production batch requires only 30 g of ingredient. Even a plant producing 100 metric tons of that finished formulation annually would consume approximately 3 kg per year.

 

As a result, the lowest Quaternium-73 price per kg may not produce the lowest total purchasing cost. Appropriate pack size, shelf life, lot consistency, documentation and manageable inventory can be more important.

 

Buyers planning to buy Quaternium-73 or establish a bulk Quaternium-73 supply program should therefore compare cost-in-use and qualification support alongside the quotation.

 

Common Quaternium-73 Regulatory Compliance Mistakes

 

Several recurring errors can create unnecessary regulatory risk.

 

The first is treating a Quaternium-73 CosIng entry or INCI recognition as proof of EU authorization. The European Commission explicitly warns against that interpretation.

 

A second is describing Quaternium-73 as “FDA approved.” FDA generally does not pre-approve cosmetic ingredients other than the relevant color additives.

 

A third is turning a supplier-recommended use level into a legal maximum. Technical formulation guidance and statutory concentration restrictions are different concepts.

 

The fourth is assuming antimicrobial activity automatically makes an ingredient an authorized preservative. In positive-list systems, the preservative function needs to be checked against the applicable legislation.

 

A fifth is assuming ingredient compliance guarantees finished-product compliance. Formula composition, exposure, safety, labeling, claims and product category still matter.

 

Finally, manufacturers should not assume that the same claims can be transferred unchanged between markets. A product positioned as a cosmetic in one country may face different claim restrictions or classification considerations elsewhere.

 

These distinctions are particularly important when regulatory text from a raw-material supplier is copied directly into a brand's marketing materials.

 

FAQ: Quaternium-73 Regulatory Status

 

Is Quaternium-73 allowed in cosmetics?

 

There is no meaningful worldwide yes-or-no answer. Quaternium-73 regulatory status must be assessed against the legislation of the target market, intended function, concentration, product category and claims. Ingredient identity and finished-product safety must also be considered.

 

Is Quaternium-73 approved in the EU?

 

It is better not to describe an ordinary cosmetic ingredient simply as “EU approved.” The EU assessment should determine whether the proposed use complies with Regulation (EC) No 1223/2009 and its applicable Annexes and whether the finished product satisfies safety and other regulatory requirements.

 

Does a CosIng listing mean Quaternium-73 is EU approved?

 

No. The European Commission explicitly states that the CosIng database has informative purposes and no legal value, and an INCI name appearing in its inventory does not mean that the ingredient is approved for cosmetic use.

 

Is Quaternium-73 an approved preservative in Europe?

 

Antimicrobial activity should not be confused with preservative authorization. EU Annex V contains the list of preservatives allowed in cosmetic products, so a manufacturer should verify the current Annex V status before assigning Quaternium-73 a legal preservative function.

 

Is Quaternium-73 FDA approved?

 

That terminology is generally inappropriate for cosmetic ingredients. FDA states that cosmetics and their ingredients do not normally undergo FDA premarket approval, apart from applicable color additives. Manufacturers remain responsible for safety and legal compliance.

 

Does Quaternium-73 have a maximum permitted concentration?

 

A single worldwide maximum should not be assumed. Technical supplier recommendations and legal limits are different. For example, Taiwan's current official preservative list includes Quaternium-73 at 0.005% under photosensitizing dyes, but that jurisdiction-specific limit should not be presented as a global standard.

 

What documents should I request before buying Quaternium-73?

 

At minimum, buyers should review the current specification, batch COA, TDS and SDS. Depending on the target market and safety assessment, additional information concerning identity, impurities, test methods, manufacturing origin and safety may be required.

 

Can the same Quaternium-73 formula be sold in the EU, USA, China and Japan?

 

Not automatically. Each market has its own regulatory structure, ingredient requirements, safety obligations, labeling rules and claim considerations. A multi-market product should therefore undergo a jurisdiction-by-jurisdiction review before commercialization.

 

A Practical Regulatory Checklist Before Purchasing Quaternium-73

 

For cosmetic manufacturers, Quaternium-73 regulatory status should be treated as a due-diligence process rather than a certificate.

 

A defensible purchasing decision begins by identifying the target market and verifying the raw material's chemical identity. Regulatory teams should then check the applicable legislation, intended function, concentration and claims before reviewing the supplier's specification, COA, TDS, SDS and supporting safety information. The representative batch should subsequently be evaluated in the intended formulation, followed by the required finished-product safety and compliance work.

 

This process separates genuine regulatory evidence from convenient but potentially misleading terms such as “CosIng approved,” “FDA approved” or “globally approved.”

 

Cosmetic manufacturers, regulatory teams and ingredient buyers evaluating Quaternium-73 can contact CHEN LANG BIO TECH for the current specification, batch COA, TDS, SDS and representative sample information.

 

Email: admin@chenlangbio.com

 

References

 

1. European Commission. CosIng – Glossary of Ingredients. The Commission states that the glossary is not a list of ingredients authorized for cosmetic use.

 

2. European Commission. Cosmetic Ingredient Database (CosIng). Includes the Commission's notice that CosIng is informative and has no legal value.

 

3. European Parliament and Council. Regulation (EC) No 1223/2009 on Cosmetic Products. Includes requirements concerning safety assessment and the regulatory Annexes, including Annex V for preservatives.

 

4. U.S. Food and Drug Administration. Cosmetics & U.S. Law. Covers cosmetic definitions, FDA premarket approval, safety responsibilities and MoCRA.

 

5. U.S. Food and Drug Administration. Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Covers safety substantiation and other industry obligations.

 

6. U.S. Food and Drug Administration. Cosmetic Ingredients. Explains that cosmetic ingredients generally do not require FDA premarket approval except applicable color additives.

 

7. U.S. Food and Drug Administration. Cosmetics Labeling Claims. Explains the regulatory distinction between cosmetic and drug claims.

 

8. Ministry of Health, Labour and Welfare, Japan. Standards for Cosmetics. Official Japanese framework concerning cosmetic ingredients and applicable restrictions.

 

9. Taiwan Food and Drug Administration. List of Preservatives Allowed in Cosmetic Products. Lists Quaternium-73 among photosensitizing dyes at a maximum concentration of 0.005%.​​​​​​​